Please use this identifier to cite or link to this item: https://hdl.handle.net/1/256
Title: Epoetin treatment: What are the arguments to expect a beneficial effect on renal disease progression?
Authors: Rossert, Jerome ;McClellan, William ;Roger, Simon D ;Verbeelen, Dierik 
Issue Date: Mar-2002
Source: Volume 17, Issue 3, pp. 359-362
Journal title: Nephrology Dialysis Transplantation
Abstract: Progression of chronic kidney disease is usually a relentless process. It is initially induced by the underlying kidney disease and its consequences. But, when nephron numbers decrease beyond a certain threshold, it is also caused by deleterious effects of this reduction in nephron number, which creates a vicious circle. Besides treatment of the underlying renal disease whenever possible, the main therapeutic tools that are available to slow the progression of renal failure are optimal control of blood pressure, use of angiotensin-converting enzyme inhibitors, and to a lesser extent dietary protein restriction (reviewed in w1x). The efficacy of these therapies is, however, limited, and the need for other treatments is highlighted by the observation that, for the past decade, the incidence of end-stage renal disease has been increasing at an annual rate of about 6–8% in most European countries. Among the other therapeutic interventions that could slow the progression of renal failure is correction of anaemia through administration of epoetin. Its potential usefulness is suggested by analysis of the pathophysiological mechanisms underlying progression of renal failure and by a few clinical studies.
Description: Open Source: http://ndt.oxfordjournals.org/content/17/3/359.short
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/256
DOI: 10.1093/ndt/17.3.359
Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/11865076
ISSN: 0931-0509
Publicaton type: Journal Article
Keywords: Kidney Disease
Anaemia
Anemia
Appears in Collections:Renal Medicine

Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.